Heron therapeutics, inc. /de/ (HRTX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net loss

-193,316

-204,749

-196,388

-201,139

-189,587

-178,840

-191,771

-195,291

-199,420

-197,484

-182,957

-189,600

-190,027

-173,143

-156,422

-130,585

-110,466

-97,591

-86,973

-83,495

-79,399

-76,367

-69,786

-63,465

-59,868

-55,283

-48,977

-42,225

-31,380

-23,348

-19,872

-17,953

-15,316

-11,814

0

0

0

Adjustments to reconcile net loss to net cash used for operating activities:
Stock-based compensation expense

45,483

51,411

50,107

48,453

43,568

33,367

30,463

29,889

30,218

30,538

30,906

30,941

28,622

25,956

24,545

19,855

17,164

14,360

10,770

9,709

7,649

8,067

8,366

10,701

12,024

10,890

10,292

8,177

6,789

5,732

4,566

3,338

2,429

1,890

0

0

0

Depreciation and amortization

2,154

2,000

1,887

1,748

1,586

1,500

1,447

1,470

1,552

1,500

1,452

1,351

1,190

1,099

1,029

900

820

734

687

662

616

578

485

423

377

333

287

252

216

197

189

179

182

179

0

0

0

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Amortization of debt discount

1,113

1,050

1,016

969

927

890

857

827

798

773

749

727

708

689

671

655

639

624

611

597

585

573

562

553

542

533

523

514

479

389

301

214

143

103

0

0

0

Realized gain on available-for-sale securities

0

8

8

8

8

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on short-term investments

2,490

3,730

4,756

4,985

4,558

3,412

1,939

974

476

278

204

90

-406

-274

-308

-285

56

-89

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of property and equipment

107

107

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-

-62

0

0

0

-

-

-

-

-39

-2

-14

-14

-9

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

-39,196

-24,773

13,322

20,935

36,294

22,778

24,782

27,270

27,386

39,914

28,851

18,616

10,327

1,960

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-110

0

0

0

Prepaid expenses and other assets

903

12,052

6,526

1,989

5,983

7,482

5,653

3,068

2,116

-3

1,615

631

-1,356

338

1,022

1,280

3,975

2,443

-980

1,377

-1,317

419

2,244

140

1,835

54

431

-179

121

318

169

467

-101

-16

0

0

0

Inventory

3,428

-14,064

-7,240

2,073

12,003

29,122

26,441

22,594

14,975

4,768

3,186

1,489

1,897

5,340

1,983

3,312

2,744

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

751

-14,105

-8,017

3,018

-647

-1,906

4,307

-1,336

6,981

11,955

-753

-2,346

-2,384

3,514

3,355

5,674

4,478

751

1,260

1,218

-1,119

1,285

-729

-2,770

482

-426

518

3,907

2,116

984

1,173

263

515

467

0

0

0

Accrued clinical and manufacturing liabilities

11,719

10,144

10,628

6,233

-2,496

-3,614

-1,236

3,570

13,710

13,713

5,678

4,931

7,489

7,976

4,672

3,143

217

1,420

637

2,637

2,774

2,038

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued payroll and employee liabilities

2,130

1,851

1,677

2,096

1,392

4,537

607

-372

-874

446

-791

2,584

3,153

3,586

5,252

2,390

1,313

2,097

788

449

344

165

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

1,664

5,560

4,788

5,235

1,099

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-272

0

0

0

Other accrued liabilities

-11,061

4,558

25,128

26,899

24,794

14,941

11,391

6,975

12,963

11,482

12,338

10,189

4,425

2,482

869

-224

1,230

1,551

2,203

1,215

2,073

2,876

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

236

627

1,097

1,298

0

0

0

Net cash used for operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used for operating activities

-108,491

-124,580

-131,090

-141,495

-179,116

-191,805

-205,467

-210,131

-181,432

-170,300

0

0

0

-

-

-

-

-78,526

-68,233

-67,581

-64,238

-60,282

-57,052

-50,170

-48,515

-40,763

-37,261

-27,713

-20,863

-17,009

-13,359

-13,211

-10,804

-7,721

0

0

0

Investing activities:
Purchases of short-term investments

378,194

477,035

384,301

543,577

585,479

497,104

428,176

185,679

91,584

121,570

93,776

137,094

112,692

43,318

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities and sales of short-term investments

394,072

462,406

0

0

0

-

-

-

-

131,783

128,784

157,151

110,215

61,329

55,829

-43,129

-23,491

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

7,956

7,154

6,726

11,232

10,403

9,171

6,830

3,367

2,519

2,553

2,108

2,648

3,239

3,135

2,749

2,466

1,592

1,086

1,804

1,634

1,709

1,438

584

1,479

1,307

1,685

1,944

1,046

984

972

933

980

936

513

0

0

0

Net cash provided by investing activities

7,922

-21,783

112,904

-64,978

-204,148

-278,550

-307,242

-87,378

12,363

7,738

32,913

-68,849

-52,698

14,876

-46,353

-15,452

-33,975

-56,960

-1,563

-1,393

-1,709

-1,438

-584

-1,479

-1,307

-1,685

-1,944

-1,046

-984

-972

-933

-980

-936

-513

0

0

0

Net proceeds from sale of common stock and/or pre-funded warrants

-

-

-

-

-

363,128

505,660

505,659

142,327

306,279

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

16,125

22,164

22,730

23,860

20,638

18,301

19,398

19,446

13,815

11,463

8,800

4,587

6,004

6,684

7,340

7,984

9,187

9,535

8,184

7,099

5,021

3,101

4,505

5,060

3,739

2,793

0

0

0

-

-

-

0

-

-

-

-

Proceeds from warrant exercises

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

600

0

0

0

-

-

-

0

-

-

-

-

Net cash provided by financing activities

180,393

186,425

24,360

577

360,150

357,608

501,119

526,166

132,131

293,731

148,643

194,430

220,522

57,455

57,730

8,368

137,643

137,991

136,573

135,488

64,028

62,108

121,251

121,812

61,575

61,229

1,754

51,166

54,125

53,513

0

0

0

-

-

-

-

Net increase (decrease) in cash and cash equivalents

79,824

40,062

6,174

-205,896

-23,114

-112,747

-11,590

228,657

-36,938

131,169

19,884

-31,666

15,497

-61,766

-107,349

-109,583

12,460

2,505

66,777

66,514

-1,919

388

63,615

70,163

11,753

18,781

-37,451

22,407

32,278

35,532

39,029

-8,889

12,359

15,865

0

0

0

Supplemental disclosure of cash flow information:
Interest paid

-

-

-

-

-

1,183

1,683

2,000

2,289

2,789

3,289

3,411

2,622

1,622

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative effect of adoption of new accounting standard

-

-

-

-

-

1,574

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-